DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Angelica Peebles - 8 Eli Lilly - 3 it's - 3 Zepbound - 2 CNBC's Angelica Peebles - 1 Morgan Stanley - 1 Mark Purcell - 1 Richard Vosser - 1
Top related locs:
U.S Danish Phoenix , Arizona Novo Paxlovid Carmel Cincinnati , Ohio Paola , Kansas
Top related orgs:
Novo Nordisk - 3 Pfizer - 2 Moderna - 2 American Heart Association - 1 cardiologists - 1 JPMorgan - 1 Citi - 1 . - 1

Search resuls for: "Angelica Peebles"


13 mentions found


☆ RSV vaccines surprise manufacturers and analysts with early success
  + stars: | 2023-11-24 | by ( Angelica Peebles | ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRSV vaccines surprise manufacturers and analysts with early successCNBC's Angelica Peebles reports on early success on a new vaccine.
Persons: CNBC's Angelica Peebles
☆ Here's what Wall Street is saying about obesity drug Wegovy following Novo Nordisk's key study
  + stars: | 2023-11-13 | by ( Alex Harring | ) www.cnbc.com   time to read: +6 min
Wegovy contains semaglutide, the same active ingredient in Novo's type 2 diabetes drug Ozempic. A rising tide for Eli Lilly? Though the study was specifically about Wegovy, Wall Street sees a positive readthrough for similar medications from other providers, particularly Eli Lilly 's Zepbound. Similarly, UBS analyst Trung Huynh called the weekend data a "best-case" scenario for Eli Lilly. And the positive outcomes for both in the Wegovy study can be viewed as encouraging for how Zepbound should perform, the analyst added.
Persons: Morgan Stanley, Mark Purcell, Richard Vosser, Peter Verdult, Eli Lilly, Eli Lilly's, Lilly, Andrew Baum, Trung Huynh, That's, it's, Zepbound, Huynh, Citi's Baum, James Shin isn't, Michael Bloom, Christina Cheddar Berk, Angelica Peebles Organizations: Novo Nordisk, American Heart Association, cardiologists, JPMorgan, Citi, ., UBS, North American, Tandem Diabetes Care, Deutsche Bank
☆ Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events
  + stars: | 2023-11-11 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com   time to read: +2 min
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. Novo Nordisk's Wegovy cut the risk of serious cardiovascular complications in people with obesity and heart disease in a closely watched trial, demonstrating a particularly large effect on heart attacks, a promising new frontier for the drug. The roughly 17,500-person Select study tested Wegovy in people with obesity and heart disease but who did not have diabetes. The new data could also help the Danish pharmaceutical company maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was approved in the U.S. earlier this week. Zepbound has been shown to help people lose more weight, but it hasn't yet demonstrated an effect on cardiovascular outcomes.
Persons: Robert Kushner, Eli Lilly, Zepbound, Howard Weintraub Organizations: Wegovy, American Heart Association Scientific Sessions, New England, of Medicine, Novo Nordisk, Northwestern University Feinberg School of Medicine, Center for, NYU Langone Locations: Danish, U.S
☆ FDA approves Eli Lilly obesity drug
  + stars: | 2023-11-08 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA approves Eli Lilly obesity drugCNBC's Angelica Peebles joins 'Halftime Report' to discuss the latest news on obesity drugs.
Persons: Eli Lilly, Angelica Peebles
☆ Wall Street is asking how weight-loss drugs will affect consumer giants — but it may be too early to tell
  + stars: | 2023-11-06 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com   time to read: +1 min
Photographer: Caitlin O'Hara/Bloomberg via Getty ImagesIf you listen to third-quarter corporate earnings calls, it might seem like everyone is taking weight-loss drugs. Delta Air Lines , PepsiCo , Philip Morris International and Darden Restaurants are just some of the companies that faced questions from analysts about how the drugs are affecting their bottom lines. While some analysts are making sweeping claims about how obesity drugs will reshape the industries they cover, the medicines are still in the early days. Known as GLP-1s, the drugs were first approved for diabetes and are now also being used for obesity. But even so, only a sliver of eligible people are actually taking the drugs at this point, said Goldman Sachs analyst Chris Shibutani.
Persons: Caitlin O'Hara, Philip Morris, it's, Nestle –, It's, Wegovy, Goldman Sachs, Chris Shibutani Organizations: PepsiCo Inc, Bloomberg, Getty, Delta Air Lines, PepsiCo, Philip, Philip Morris International, Darden, Hershey, Conagra, Nestle, Novo Nordisk Locations: Phoenix , Arizona, U.S, Novo
☆ GSK beats on top and bottom lines after strong launch of RSV vaccine
  + stars: | 2023-11-01 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGSK beats on top and bottom lines after strong launch of RSV vaccineCNBC's Angelica Peebles joins 'Squawk Box' to break down the company's quarterly earnings results.
Persons: Angelica Peebles Organizations: GSK
☆ Dexcom stock climbs as worries surrounding weight-loss drugs fades
  + stars: | 2023-10-27 | by ( Angelica Peebles | ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDexcom stock climbs as worries surrounding weight-loss drugs fadesCNBC's Angelica Peebles joins 'Closing Bell Overtime' to take a closer look at stock movers in the healthcare sector.
Persons: Angelica Peebles
☆ RBC lists antibody-drug conjugates (ADCs) as $30 billion category by 2030
  + stars: | 2023-10-23 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRBC lists antibody-drug conjugates (ADCs) as $30 billion category by 2030CNBC's Angelica Peebles reports on opportunities in the pharmaceutical sector.
Persons: Angelica Peebles Organizations: RBC
☆ Pfizer to price Covid drug Paxlovid at $1,390 per course
  + stars: | 2023-10-18 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Pfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to transition it to the commercial market later this year. A company spokesperson on Wednesday confirmed the price, which was first reported by The Wall Street Journal. But beginning in 2024, Pfizer will sell Paxlovid directly to health insurers, which comes as demand for Covid vaccines and treatments slumps nationwide. But health insurance plans will likely pay much less than the nearly $1,400 list price for Paxlovid, meaning patients will probably have small or no out-of-pocket costs. Overall, Pfizer now expects 2023 sales of $58 billion to $61 billion, down from its previous guidance of $67 billion to $70 billion.
Persons: Angelica Peebles Organizations: Pfizer, Wednesday, Wall Street, Paxlovid, FDA, CNBC Locations: Paxlovid
☆ New RSV protections for infants hit cost, insurance hurdles in U.S. rollout
  + stars: | 2023-10-13 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com   time to read: +2 min
Two new immunizations promise to protect babies from respiratory syncytial virus – if people can find them. Providers are scrambling to offer Pfizer's vaccine, Abrysvo, to pregnant patients and Sanofi's monoclonal antibody, Beyfortus, to babies. Until now, the only preventative treatment was another monoclonal antibody called Synagis that's given once a month during RSV season, which generally runs from fall through spring. Sanofi's Beyfortus is a monoclonal antibody that's given directly to babies and provides them with immediate protection. "I know that [RSV]'s a threat to little babies, and so to have an opportunity to prevent illness in the first place is really exciting."
Persons: Michael Chamberlin, hasn't, we're, Chamberlin, that's, Erin Bakke, Graham Organizations: Pediatric Associates Locations: Carmel, Cincinnati , Ohio
☆ Providers struggle to get latest Covid shots into arms amid early supply issues
  + stars: | 2023-09-21 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com   time to read: +3 min
Some are being told they need to pay more than $100 out of pocket because their insurance provider isn't covering the shots yet. Most Walgreens stores have enough supply for existing appointments and more slots are being made available as the shots come in, a spokesperson said. Previously, the government purchased the shots and distributed them to pharmacies, doctor's offices and other providers. That leaves pharmacies like his fielding calls and explaining they can't administer shots yet if they wanted to. A notice on Walgreens' website said appointments for children under 12 years old won't start until Friday, Sept. 29.
Persons: Cencora, McKesson, Health —, Nate Rockers, they're, Theresa Tolle, Tolle, it's, they'll Organizations: Walgreens, Moderna, Pfizer, Health, Rockers Pharmacy, Pharmacy, Rockers, CVS, Walmart Locations: Paola , Kansas, Sebastian , Florida
☆ CDC recommends updated COVID-19 booster to everyone six months and older
  + stars: | 2023-09-12 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCDC recommends updated COVID-19 booster to everyone six months and olderCNBC's Angelica Peebles reports on breaking news from the CDC concerning new COVID boosters.
Persons: Angelica Peebles Organizations: CDC
☆ Moderna: Updated Covid vaccine is effective against newer variant
  + stars: | 2023-09-06 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna: Updated Covid vaccine is effective against newer variantCNBC's Angelica Peebles reports on the latest news from Moderna.
Persons: Angelica Peebles Organizations: Moderna
0 next >>
Total: 13